173 related articles for article (PubMed ID: 37907492)
1. An Insight into Hepatitis C Virus: In Search of Promising Drug Targets.
Dwivedi M; Dwivedi A; Mukherjee D
Curr Drug Targets; 2023; 24(14):1127-1138. PubMed ID: 37907492
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
3. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
Chen SH; Tan SL
Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of chronic viral hepatitis C with direct acting antiviral agent: review].
Malov VA; Ubeeva EA; Ubeeva IP; Nikolaev SM; Umbetova KT
Ter Arkh; 2019 Nov; 91(11):86-89. PubMed ID: 32598617
[TBL] [Abstract][Full Text] [Related]
5. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA
Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060
[TBL] [Abstract][Full Text] [Related]
6. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C Virus NS3/4A Protease Inhibitors.
López-Labrador FX
Recent Pat Antiinfect Drug Discov; 2008 Nov; 3(3):157-67. PubMed ID: 18991798
[TBL] [Abstract][Full Text] [Related]
8. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C Virus.
Pietschmann T; Brown RJP
Trends Microbiol; 2019 Apr; 27(4):379-380. PubMed ID: 30709707
[TBL] [Abstract][Full Text] [Related]
10. Anti-hepatitis C virus activity and synergistic effect of Nymphaea alba extracts and bioactive constituents in liver infected cells.
Rehman S; Ashfaq UA; Ijaz B; Riazuddin S
Microb Pathog; 2018 Aug; 121():198-209. PubMed ID: 29775725
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus infection.
Manns MP; Buti M; Gane E; Pawlotsky JM; Razavi H; Terrault N; Younossi Z
Nat Rev Dis Primers; 2017 Mar; 3():17006. PubMed ID: 28252637
[TBL] [Abstract][Full Text] [Related]
12. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
[TBL] [Abstract][Full Text] [Related]
13. Emerging antiviral drugs for hepatitis C virus.
Enomoto M; Tamori A; Kawada N
Rev Recent Clin Trials; 2009 Sep; 4(3):179-84. PubMed ID: 20028330
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antivirals: the endgame for hepatitis C?
D'Ambrosio R; Degasperi E; Colombo M; Aghemo A
Curr Opin Virol; 2017 Jun; 24():31-37. PubMed ID: 28419938
[TBL] [Abstract][Full Text] [Related]
15. Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy.
Das D; Pandya M
Mini Rev Med Chem; 2018; 18(7):584-596. PubMed ID: 28901852
[TBL] [Abstract][Full Text] [Related]
16. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.
Shi N; Hiraga N; Imamura M; Hayes CN; Zhang Y; Kosaka K; Okazaki A; Murakami E; Tsuge M; Abe H; Aikata H; Takahashi S; Ochi H; Tateno-Mukaidani C; Yoshizato K; Matsui H; Kanai A; Inaba T; McPhee F; Gao M; Chayama K
Gut; 2013 Jul; 62(7):1055-61. PubMed ID: 23322441
[TBL] [Abstract][Full Text] [Related]
17. Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients.
El-Tahan RR; Ghoneim AM; Zaghloul H
Virus Genes; 2020 Oct; 56(5):564-581. PubMed ID: 32572756
[TBL] [Abstract][Full Text] [Related]
18. Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a.
Kiattanaphon A; Vipsoongnern Y; Kunthalert D; Sistayanarain A
Mol Biol Rep; 2022 Oct; 49(10):9437-9443. PubMed ID: 36002650
[TBL] [Abstract][Full Text] [Related]
19. Recent development of therapeutics for chronic HCV infection.
Huang Z; Murray MG; Secrist JA
Antiviral Res; 2006 Sep; 71(2-3):351-62. PubMed ID: 16828888
[TBL] [Abstract][Full Text] [Related]
20. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
